NCT07664358 Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury
| NCT ID | NCT07664358 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Fibrinogen |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2026-07-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
this study aims to assess the ability of fibrinogen-to-albumin ratio to predict the development of Acute respiratory distress syndrome in traumatic brain injury patients.
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years admitted to the ICU with traumatic Brain Injury * Admission to the ICU within 24 hours of injury. * Patients will be expected to remain under hospital care for follow-up * Availability of fibrinogen and albumin measurements within the first 24 hours of ICU admission. * Informed consent will be obtained from a legally authorized representative. Exclusion Criteria: * Preexisting advanced chronic liver disease, nephrotic syndrome, or protein-losing enteropathy. * Pre-existing ARDS on admission. * Recipient of albumin, fibrinogen concentrate, or cryoprecipitate before admission sampling. * Use of anticoagulant or fibrinolytic therapy before admission. * Active malignancy or severe systemic infection at admission. * Direct sever lung injury * Pregnancy * Refusal of consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07664358 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fibrinogen. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07664358 currently recruiting?
Yes, NCT07664358 is actively recruiting participants. Contact the research team at emantaher6669@gmail.com for enrollment information.
Where is the NCT07664358 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07664358 clinical trial?
NCT07664358 is sponsored by Tanta University. The trial plans to enroll 350 participants.